<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12558" end="12569" sStart="11405" offset="1153" sid="null" wn="1" wnkey="recommend%2:32:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10171" end="10182" sStart="null" offset="113" sid="null" wn="1" wnkey="recommend%2:32:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="10171" end="10182" sStart="null" offset="113" sid="r11.recommend.v.0373" wn="1" wnkey="recommend%2:32:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12558" end="12569" sStart="null" offset="1153" sid="null" wn="1" wnkey="recommend%2:32:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10171" end="10182" sStart="null" offset="113" sid="null" wn="1" wnkey="recommend%2:32:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="12558" end="12569" sStart="null" offset="1153" sid="r11.recommend.v.0374" wn="2147483645" wnkey="null" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12558" end="12569" sStart="null" offset="1153" sid="r11.recommend.v.0006" wn="1" wnkey="recommend%2:32:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10171" end="10182" sStart="null" offset="113" sid="r11.recommend.v.0005" wn="1" wnkey="recommend%2:32:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12558" end="12569" sStart="null" offset="1153" sid="null" wn="1" wnkey="recommend%2:32:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10171" end="10182" sStart="null" offset="113" sid="null" wn="1" wnkey="recommend%2:32:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12558" end="12569" sStart="null" offset="1153" sid="r11.recommend.v.0006" wn="1" wnkey="recommend%2:32:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10171" end="10182" sStart="null" offset="113" sid="r11.recommend.v.0005" wn="1" wnkey="recommend%2:32:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9959" end="9963" sStart="null" offset="160" sid="null" wn="1" wnkey="rate%1:28:00::" text="Third, despite the high risk nature of enrolled patients (ie, electrocardiogram [ECG] changes and/or other objective evidence of ischemia), the rate of platelet glycoprotein IIb/IIIa inhibitor utilization was quite low (1." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="7832" end="7838" sStart="null" offset="18" sid="r8.number.n.0976" wn="1" wnkey="number%1:07:00::" text="There were also a number of limitations that may have hampered the study's generalizability." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="6259" end="6263" sStart="null" offset="42" sid="null" wn="" wnkey="null" text="Furthermore, while the number of patients lost to follow up was small, if adverse events had occurred in those treated with atorvastatin (n = 3) but not placebo (n = 8), the overall trial results may have been neutral rather than positive." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="2434" end="2440" sStart="null" offset="134" sid="r9.level.n.0941" wn="1" wnkey="level%1:07:00::" text="Secondary endpoints included stroke, worsening heart failure, need for coronary revascularization and change in lipid levels throughout the study." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3672" end="3678" sStart="null" offset="99" sid="r9.level.n.0105" wn="1" wnkey="level%1:07:00::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10661" end="10667" sStart="null" offset="191" sid="r9.level.n.0086" wn="1" wnkey="level%1:07:00::" text="The small difference in number of primary endpoint events between atorvastatin and placebo groups make it difficult to dissect the relationship between baseline lipid levels and treatment effect further." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10462" end="10468" sStart="null" offset="404" sid="r9.level.n.0066" wn="1" wnkey="level%1:07:00::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1792" end="1797" sStart="null" offset="306" sid="r9.level.n.0050" wn="1" wnkey="level%1:07:00::" text="MIRACL enrolled 3,086 patients within 24-96 hours (mean 63 hours) of admission for unstable angina or a non-Q-wave myocardial infarction and randomized them to 16 weeks of atorvastatin 80 mg or placebo once daily [ 5 ] . The major exclusion criteria were: total cholesterol level greater than 270 mg/dL; Q-wave myocardial infarction on admission or during the previous month; and, coronary revascularization in the months before admission, during the index hospitalization or anticipated following hospital discharge." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12834" end="12839" sStart="null" offset="1429" sid="r9.level.n.0028" wn="1" wnkey="level%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2636" end="2641" sStart="null" offset="165" sid="r9.level.n.0025" wn="1" wnkey="level%1:07:00::" text="On average, patients were 65 years of age, approximately 65% were men, 86% Caucasian and the mean baseline low density lipoprotein (LDL) cholesterol level was 124 mg/dL." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2434" end="2440" sStart="null" offset="134" sid="r9.level.n.0011" wn="1" wnkey="level%1:07:00::" text="Secondary endpoints included stroke, worsening heart failure, need for coronary revascularization and change in lipid levels throughout the study." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12214" end="12220" sStart="null" offset="809" sid="r9.level.n.0107" wn="1" wnkey="level%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10661" end="10667" sStart="null" offset="191" sid="r9.level.n.0086" wn="1" wnkey="level%1:07:00::" text="The small difference in number of primary endpoint events between atorvastatin and placebo groups make it difficult to dissect the relationship between baseline lipid levels and treatment effect further." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10462" end="10468" sStart="null" offset="404" sid="r9.level.n.0066" wn="1" wnkey="level%1:07:00::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1792" end="1797" sStart="null" offset="306" sid="r9.level.n.0050" wn="1" wnkey="level%1:07:00::" text="MIRACL enrolled 3,086 patients within 24-96 hours (mean 63 hours) of admission for unstable angina or a non-Q-wave myocardial infarction and randomized them to 16 weeks of atorvastatin 80 mg or placebo once daily [ 5 ] . The major exclusion criteria were: total cholesterol level greater than 270 mg/dL; Q-wave myocardial infarction on admission or during the previous month; and, coronary revascularization in the months before admission, during the index hospitalization or anticipated following hospital discharge." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12834" end="12839" sStart="null" offset="1429" sid="r9.level.n.0028" wn="1" wnkey="level%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2636" end="2641" sStart="null" offset="165" sid="r9.level.n.0025" wn="1" wnkey="level%1:07:00::" text="On average, patients were 65 years of age, approximately 65% were men, 86% Caucasian and the mean baseline low density lipoprotein (LDL) cholesterol level was 124 mg/dL." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2434" end="2440" sStart="null" offset="134" sid="r9.level.n.0011" wn="1" wnkey="level%1:07:00::" text="Secondary endpoints included stroke, worsening heart failure, need for coronary revascularization and change in lipid levels throughout the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="3672" end="3678" sStart="null" offset="99" sid="r9.level.n.0432" wn="2" wnkey="level%1:26:01::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10661" end="10667" sStart="null" offset="191" sid="r9.level.n.0086" wn="2" wnkey="level%1:26:01::" text="The small difference in number of primary endpoint events between atorvastatin and placebo groups make it difficult to dissect the relationship between baseline lipid levels and treatment effect further." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10462" end="10468" sStart="null" offset="404" sid="r9.level.n.0066" wn="2" wnkey="level%1:26:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1792" end="1797" sStart="null" offset="306" sid="r9.level.n.0050" wn="2" wnkey="level%1:26:01::" text="MIRACL enrolled 3,086 patients within 24-96 hours (mean 63 hours) of admission for unstable angina or a non-Q-wave myocardial infarction and randomized them to 16 weeks of atorvastatin 80 mg or placebo once daily [ 5 ] . The major exclusion criteria were: total cholesterol level greater than 270 mg/dL; Q-wave myocardial infarction on admission or during the previous month; and, coronary revascularization in the months before admission, during the index hospitalization or anticipated following hospital discharge." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12834" end="12839" sStart="null" offset="1429" sid="r9.level.n.0028" wn="2" wnkey="level%1:26:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2636" end="2641" sStart="null" offset="165" sid="r9.level.n.0025" wn="2" wnkey="level%1:26:01::" text="On average, patients were 65 years of age, approximately 65% were men, 86% Caucasian and the mean baseline low density lipoprotein (LDL) cholesterol level was 124 mg/dL." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2434" end="2440" sStart="null" offset="134" sid="r9.level.n.0011" wn="2" wnkey="level%1:26:01::" text="Secondary endpoints included stroke, worsening heart failure, need for coronary revascularization and change in lipid levels throughout the study." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="11098" end="11104" sStart="null" offset="392" sid="r9.level.n.0106" wn="1" wnkey="level%1:07:00::" text="Consequently, it remains uncertain whether one can extrapolate the MIRACL trial results to those who undergo coronary revascularization shortly before or after a coronary event, who present with a Q-wave myocardial infarction, who are treated with platelet glycoprotein IIb/IIIa inhibitors, or who have relatively low admission LDL cholesterol levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10661" end="10667" sStart="null" offset="191" sid="r9.level.n.0086" wn="1" wnkey="level%1:07:00::" text="The small difference in number of primary endpoint events between atorvastatin and placebo groups make it difficult to dissect the relationship between baseline lipid levels and treatment effect further." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10462" end="10468" sStart="null" offset="404" sid="r9.level.n.0066" wn="1" wnkey="level%1:07:00::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1792" end="1797" sStart="null" offset="306" sid="r9.level.n.0050" wn="1" wnkey="level%1:07:00::" text="MIRACL enrolled 3,086 patients within 24-96 hours (mean 63 hours) of admission for unstable angina or a non-Q-wave myocardial infarction and randomized them to 16 weeks of atorvastatin 80 mg or placebo once daily [ 5 ] . The major exclusion criteria were: total cholesterol level greater than 270 mg/dL; Q-wave myocardial infarction on admission or during the previous month; and, coronary revascularization in the months before admission, during the index hospitalization or anticipated following hospital discharge." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12834" end="12839" sStart="null" offset="1429" sid="r9.level.n.0028" wn="1" wnkey="level%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2636" end="2641" sStart="null" offset="165" sid="r9.level.n.0025" wn="1" wnkey="level%1:07:00::" text="On average, patients were 65 years of age, approximately 65% were men, 86% Caucasian and the mean baseline low density lipoprotein (LDL) cholesterol level was 124 mg/dL." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="2434" end="2440" sStart="null" offset="134" sid="r9.level.n.0011" wn="1" wnkey="level%1:07:00::" text="Secondary endpoints included stroke, worsening heart failure, need for coronary revascularization and change in lipid levels throughout the study." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="7770" end="7774" sStart="null" offset="18" sid="r9.late.j.0853" wn="2" wnkey="late%5:00:00:unpunctual:00" text="Unfortunately, no late clinical follow up is planned." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7770" end="7774" sStart="null" offset="18" sid="r9.late.j.0032" wn="1" wnkey="late%3:00:00::" text="Unfortunately, no late clinical follow up is planned." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7770" end="7774" sStart="null" offset="18" sid="r9.late.j.0032" wn="1" wnkey="late%3:00:00::" text="Unfortunately, no late clinical follow up is planned." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7770" end="7774" sStart="null" offset="18" sid="r9.late.j.0032" wn="6" wnkey="late%3:00:02::" text="Unfortunately, no late clinical follow up is planned." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7770" end="7774" sStart="null" offset="18" sid="r9.late.j.0032" wn="2147483644" wnkey="null" text="Unfortunately, no late clinical follow up is planned." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="null" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="null" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="r10.high.j.0098" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="r10.high.j.0060" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9818" end="9822" sStart="null" offset="19" sid="r10.high.j.0017" wn="1" wnkey="high%3:00:02::" text="Third, despite the high risk nature of enrolled patients (ie, electrocardiogram [ECG] changes and/or other objective evidence of ischemia), the rate of platelet glycoprotein IIb/IIIa inhibitor utilization was quite low (1." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10137" end="10141" sStart="null" offset="79" sid="r10.high.j.0006" wn="1" wnkey="high%3:00:02::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="null" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="null" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="r10.high.j.0098" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="r10.high.j.0060" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9818" end="9822" sStart="null" offset="19" sid="r10.high.j.0017" wn="1" wnkey="high%3:00:02::" text="Third, despite the high risk nature of enrolled patients (ie, electrocardiogram [ECG] changes and/or other objective evidence of ischemia), the rate of platelet glycoprotein IIb/IIIa inhibitor utilization was quite low (1." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10137" end="10141" sStart="null" offset="79" sid="r10.high.j.0006" wn="1" wnkey="high%3:00:02::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="null" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="null" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="r10.high.j.0098" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="r10.high.j.0060" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9818" end="9822" sStart="null" offset="19" sid="r10.high.j.0017" wn="1" wnkey="high%3:00:02::" text="Third, despite the high risk nature of enrolled patients (ie, electrocardiogram [ECG] changes and/or other objective evidence of ischemia), the rate of platelet glycoprotein IIb/IIIa inhibitor utilization was quite low (1." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10137" end="10141" sStart="null" offset="79" sid="r10.high.j.0006" wn="1" wnkey="high%3:00:02::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="null" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="null" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="3712" end="3716" sStart="null" offset="139" sid="r10.high.j.0098" wn="1" wnkey="high%3:00:02::" text="Atorvastatin also significantly reduced total and LDL cholesterol and triglyceride levels but did not significantly change high density lipoprotein (HDL) cholesterol by 16 weeks." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16552" end="16556" sStart="null" offset="233" sid="r10.high.j.0060" wn="1" wnkey="high%3:00:02::" text="HMG CoA = 3-Hydroxy-3-methylgluatryl coenzyme A; MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; LDL = low density lipoprotein; RR = relative risk; CI = confidence interval; HDL = high density lipoprotein; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft; ECG = electrocardiogram; A-2-Z = Aggrastat to Zocor; ACS = acute coronary syndrome; PROVE IT = Pravastatin or Atorvastatin Evaluation and Infection Therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9818" end="9822" sStart="null" offset="19" sid="r10.high.j.0017" wn="1" wnkey="high%3:00:02::" text="Third, despite the high risk nature of enrolled patients (ie, electrocardiogram [ECG] changes and/or other objective evidence of ischemia), the rate of platelet glycoprotein IIb/IIIa inhibitor utilization was quite low (1." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10137" end="10141" sStart="null" offset="79" sid="r10.high.j.0006" wn="1" wnkey="high%3:00:02::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="386" end="391" sStart="null" offset="13" sid="r10.find.v.0209" wn="4" wnkey="find%2:32:00::" text="These trials found that when compared with placebo, statins significantly reduced the incidence of death, myocardial infarction, unstable angina, percutaneous and surgical coronary revascularization, and stroke in persons with stable coronary disease." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1468-6708-3-3.anc" start="8828" end="8832" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="The investigators reasoned that recurrent ischemic events in this population were likely to result from restenosis or bypass graft closure and that statins would be less likely to affect these processes [ 8 ] . Nevertheless, a number of trials have established the benefits of statin therapy early after coronary revascularization [ 9 10 11 ] . Furthermore, a number of recent trials have suggested that higher risk patients with non-ST elevation acute coronary syndromes &lt;b&gt;fair&lt;/b&gt; better when an early invasive strategy is applied [ 12 13 14 ] and it is not uncommon for patients to be treated in this fashion." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9144" end="9155" sStart="null" offset="157" sid="null" wn="" wnkey="null" text="Second, patients with Q-wave myocardial infarction were not eligible for enrollment because it was felt that statins would not influence the development of important prognostic determinants such as left ventricular systolic dysfunction, ventricular arrhythmias or mechanical complications [ 5 ] . Nevertheless, patients who develop electrocardiographic Q-waves represent a substantial proportion of all patients with myocardial infarction." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="9144" end="9155" sStart="null" offset="157" sid="null" wn="3" wnkey="development%1:22:01::" text="Second, patients with Q-wave myocardial infarction were not eligible for enrollment because it was felt that statins would not influence the development of important prognostic determinants such as left ventricular systolic dysfunction, ventricular arrhythmias or mechanical complications [ 5 ] . Nevertheless, patients who develop electrocardiographic Q-waves represent a substantial proportion of all patients with myocardial infarction." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="13013" end="13017" sStart="null" offset="1608" sid="null" wn="4" wnkey="date%1:28:02::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15923" end="15934" sStart="null" offset="257" sid="null" wn="1" wnkey="combination%1:14:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="15923" end="15934" sStart="null" offset="257" sid="r11.combination.n.0799" wn="1" wnkey="combination%1:14:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15923" end="15934" sStart="null" offset="257" sid="null" wn="1" wnkey="combination%1:14:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15923" end="15934" sStart="null" offset="257" sid="r11.combination.n.0004" wn="1" wnkey="combination%1:14:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15923" end="15934" sStart="null" offset="257" sid="null" wn="2147483645" wnkey="null" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15923" end="15934" sStart="null" offset="257" sid="r11.combination.n.0004" wn="2147483646" wnkey="null" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="null" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="r10.board.n.0012" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="null" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="r10.board.n.0012" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="null" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="r10.board.n.0548" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="r10.board.n.0012" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="null" wn="" wnkey="null" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="null" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16215" end="16220" sStart="null" offset="67" sid="r10.board.n.0012" wn="1" wnkey="board%1:14:00::" text="Dr Aronow has received honoraria as a speaker and advisory board member for Pfizer and as a speaker for Merck." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16089" end="16096" sStart="null" offset="423" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15904" end="15911" sStart="null" offset="238" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14542" end="14550" sStart="null" offset="11" sid="null" wn="2" wnkey="benefit%1:07:00::" text="If benefits accrue, but do so later during follow up, it would be difficult to discriminate between the effects of more aggressive vs. earlier lipid lowering therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12770" end="12778" sStart="null" offset="1365" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="11303" end="11311" sStart="null" offset="135" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Although MIRACL and the two aforementioned cohort studies suggest that lipid-lowering agents exert short-term clinical benefits when initiated soon after an acute coronary syndrome, this remains an open question." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="8588" end="8596" sStart="null" offset="305" sid="null" wn="2" wnkey="benefit%1:07:00::" text="The investigators reasoned that recurrent ischemic events in this population were likely to result from restenosis or bypass graft closure and that statins would be less likely to affect these processes [ 8 ] . Nevertheless, a number of trials have established the benefits of statin therapy early after coronary revascularization [ 9 10 11 ] . Furthermore, a number of recent trials have suggested that higher risk patients with non-ST elevation acute coronary syndromes fair better when an early invasive strategy is applied [ 12 13 14 ] and it is not uncommon for patients to be treated in this fashion." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7231" end="7238" sStart="null" offset="39" sid="null" wn="2" wnkey="benefit%1:07:00::" text="While it is impressive that a clinical benefit was realized after only 16 weeks of statin therapy, the increased risk of adverse clinical events persists throughout the year following an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4835" end="4842" sStart="null" offset="100" sid="null" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1048" end="1055" sStart="null" offset="65" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Whether lipid-lowering therapy would provide incremental benefit if initiated immediately following an acute coronary syndrome is an important issue as the risk of a recurrent adverse cardiac events is much greater in patients with unstable coronary disease than in the stable setting." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="15904" end="15911" sStart="null" offset="238" sid="r11.benefit.n.0649" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="4917" end="4924" sStart="null" offset="182" sid="r11.benefit.n.0610" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="14446" end="14453" sStart="null" offset="175" sid="r11.benefit.n.0394" wn="2" wnkey="benefit%1:07:00::" text="If A-2-Z demonstrates significant reductions in the incidence of adverse events during the first four months, it would suggest an incremental clinical benefit from initiating these agents early after an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16089" end="16096" sStart="null" offset="423" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15904" end="15911" sStart="null" offset="238" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14542" end="14550" sStart="null" offset="11" sid="null" wn="2" wnkey="benefit%1:07:00::" text="If benefits accrue, but do so later during follow up, it would be difficult to discriminate between the effects of more aggressive vs. earlier lipid lowering therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12770" end="12778" sStart="null" offset="1365" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="11303" end="11311" sStart="null" offset="135" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Although MIRACL and the two aforementioned cohort studies suggest that lipid-lowering agents exert short-term clinical benefits when initiated soon after an acute coronary syndrome, this remains an open question." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="8588" end="8596" sStart="null" offset="305" sid="null" wn="2" wnkey="benefit%1:07:00::" text="The investigators reasoned that recurrent ischemic events in this population were likely to result from restenosis or bypass graft closure and that statins would be less likely to affect these processes [ 8 ] . Nevertheless, a number of trials have established the benefits of statin therapy early after coronary revascularization [ 9 10 11 ] . Furthermore, a number of recent trials have suggested that higher risk patients with non-ST elevation acute coronary syndromes fair better when an early invasive strategy is applied [ 12 13 14 ] and it is not uncommon for patients to be treated in this fashion." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7231" end="7238" sStart="null" offset="39" sid="null" wn="2" wnkey="benefit%1:07:00::" text="While it is impressive that a clinical benefit was realized after only 16 weeks of statin therapy, the increased risk of adverse clinical events persists throughout the year following an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4835" end="4842" sStart="null" offset="100" sid="null" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1048" end="1055" sStart="null" offset="65" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Whether lipid-lowering therapy would provide incremental benefit if initiated immediately following an acute coronary syndrome is an important issue as the risk of a recurrent adverse cardiac events is much greater in patients with unstable coronary disease than in the stable setting." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="7231" end="7238" sStart="null" offset="39" sid="r11.benefit.n.0725" wn="2" wnkey="benefit%1:07:00::" text="While it is impressive that a clinical benefit was realized after only 16 weeks of statin therapy, the increased risk of adverse clinical events persists throughout the year following an acute coronary syndrome." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="12770" end="12778" sStart="null" offset="1365" sid="r11.benefit.n.0668" wn="2" wnkey="benefit%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="13250" end="13257" sStart="null" offset="64" sid="r11.benefit.n.0191" wn="2" wnkey="benefit%1:07:00::" text="The ascertainment and quantification of any incremental benefit conferred by statin therapy initiated early after an acute coronary syndrome will require confirmation." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16089" end="16096" sStart="null" offset="423" sid="r11.benefit.n.0020" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15904" end="15911" sStart="null" offset="238" sid="r11.benefit.n.0019" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14542" end="14550" sStart="null" offset="11" sid="r11.benefit.n.0018" wn="2" wnkey="benefit%1:07:00::" text="If benefits accrue, but do so later during follow up, it would be difficult to discriminate between the effects of more aggressive vs. earlier lipid lowering therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14446" end="14453" sStart="null" offset="175" sid="r11.benefit.n.0017" wn="2" wnkey="benefit%1:07:00::" text="If A-2-Z demonstrates significant reductions in the incidence of adverse events during the first four months, it would suggest an incremental clinical benefit from initiating these agents early after an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="13250" end="13257" sStart="null" offset="64" sid="r11.benefit.n.0016" wn="2" wnkey="benefit%1:07:00::" text="The ascertainment and quantification of any incremental benefit conferred by statin therapy initiated early after an acute coronary syndrome will require confirmation." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12770" end="12778" sStart="null" offset="1365" sid="r11.benefit.n.0015" wn="2" wnkey="benefit%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="11303" end="11311" sStart="null" offset="135" sid="r11.benefit.n.0014" wn="2" wnkey="benefit%1:07:00::" text="Although MIRACL and the two aforementioned cohort studies suggest that lipid-lowering agents exert short-term clinical benefits when initiated soon after an acute coronary syndrome, this remains an open question." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="8588" end="8596" sStart="null" offset="305" sid="r11.benefit.n.0013" wn="2" wnkey="benefit%1:07:00::" text="The investigators reasoned that recurrent ischemic events in this population were likely to result from restenosis or bypass graft closure and that statins would be less likely to affect these processes [ 8 ] . Nevertheless, a number of trials have established the benefits of statin therapy early after coronary revascularization [ 9 10 11 ] . Furthermore, a number of recent trials have suggested that higher risk patients with non-ST elevation acute coronary syndromes fair better when an early invasive strategy is applied [ 12 13 14 ] and it is not uncommon for patients to be treated in this fashion." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7231" end="7238" sStart="null" offset="39" sid="r11.benefit.n.0012" wn="2" wnkey="benefit%1:07:00::" text="While it is impressive that a clinical benefit was realized after only 16 weeks of statin therapy, the increased risk of adverse clinical events persists throughout the year following an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4917" end="4924" sStart="null" offset="182" sid="r11.benefit.n.0011" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4835" end="4842" sStart="null" offset="100" sid="r11.benefit.n.0010" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4709" end="4717" sStart="null" offset="301" sid="r11.benefit.n.0009" wn="2" wnkey="benefit%1:07:00::" text="Although lipid-lowering therapy was associated with a significantly lower mortality when initiated early after an acute coronary syndrome in two large observational studies [ 6 7 ] , MIRACL was the first randomized trial to suggest that statins confer clinical benefits in this setting." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1048" end="1055" sStart="null" offset="65" sid="r11.benefit.n.0008" wn="2" wnkey="benefit%1:07:00::" text="Whether lipid-lowering therapy would provide incremental benefit if initiated immediately following an acute coronary syndrome is an important issue as the risk of a recurrent adverse cardiac events is much greater in patients with unstable coronary disease than in the stable setting." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16089" end="16096" sStart="null" offset="423" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15904" end="15911" sStart="null" offset="238" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14542" end="14550" sStart="null" offset="11" sid="null" wn="2" wnkey="benefit%1:07:00::" text="If benefits accrue, but do so later during follow up, it would be difficult to discriminate between the effects of more aggressive vs. earlier lipid lowering therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12770" end="12778" sStart="null" offset="1365" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="11303" end="11311" sStart="null" offset="135" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Although MIRACL and the two aforementioned cohort studies suggest that lipid-lowering agents exert short-term clinical benefits when initiated soon after an acute coronary syndrome, this remains an open question." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="8588" end="8596" sStart="null" offset="305" sid="null" wn="2" wnkey="benefit%1:07:00::" text="The investigators reasoned that recurrent ischemic events in this population were likely to result from restenosis or bypass graft closure and that statins would be less likely to affect these processes [ 8 ] . Nevertheless, a number of trials have established the benefits of statin therapy early after coronary revascularization [ 9 10 11 ] . Furthermore, a number of recent trials have suggested that higher risk patients with non-ST elevation acute coronary syndromes fair better when an early invasive strategy is applied [ 12 13 14 ] and it is not uncommon for patients to be treated in this fashion." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7231" end="7238" sStart="null" offset="39" sid="null" wn="2" wnkey="benefit%1:07:00::" text="While it is impressive that a clinical benefit was realized after only 16 weeks of statin therapy, the increased risk of adverse clinical events persists throughout the year following an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4835" end="4842" sStart="null" offset="100" sid="null" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1048" end="1055" sStart="null" offset="65" sid="null" wn="2" wnkey="benefit%1:07:00::" text="Whether lipid-lowering therapy would provide incremental benefit if initiated immediately following an acute coronary syndrome is an important issue as the risk of a recurrent adverse cardiac events is much greater in patients with unstable coronary disease than in the stable setting." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="1048" end="1055" sStart="null" offset="65" sid="r11.benefit.n.0546" wn="2" wnkey="benefit%1:07:00::" text="Whether lipid-lowering therapy would provide incremental benefit if initiated immediately following an acute coronary syndrome is an important issue as the risk of a recurrent adverse cardiac events is much greater in patients with unstable coronary disease than in the stable setting." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-3.anc" start="11303" end="11311" sStart="null" offset="135" sid="r11.benefit.n.0237" wn="2" wnkey="benefit%1:07:00::" text="Although MIRACL and the two aforementioned cohort studies suggest that lipid-lowering agents exert short-term clinical benefits when initiated soon after an acute coronary syndrome, this remains an open question." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="16089" end="16096" sStart="null" offset="423" sid="r11.benefit.n.0020" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="15904" end="15911" sStart="null" offset="238" sid="r11.benefit.n.0019" wn="2" wnkey="benefit%1:07:00::" text="Future secondary prevention studies should look at patients with stable or unstable disease and will need to address the comparative efficacy of different statins (or newer agents), assess the incremental benefit of combination therapy [ 30 ] and determine whether there is a serum cholesterol 'floor' below which reductions are unlikely to provide further clinical benefit." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14542" end="14550" sStart="null" offset="11" sid="r11.benefit.n.0018" wn="2" wnkey="benefit%1:07:00::" text="If benefits accrue, but do so later during follow up, it would be difficult to discriminate between the effects of more aggressive vs. earlier lipid lowering therapy." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="14446" end="14453" sStart="null" offset="175" sid="r11.benefit.n.0017" wn="2" wnkey="benefit%1:07:00::" text="If A-2-Z demonstrates significant reductions in the incidence of adverse events during the first four months, it would suggest an incremental clinical benefit from initiating these agents early after an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="13250" end="13257" sStart="null" offset="64" sid="r11.benefit.n.0016" wn="2" wnkey="benefit%1:07:00::" text="The ascertainment and quantification of any incremental benefit conferred by statin therapy initiated early after an acute coronary syndrome will require confirmation." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12770" end="12778" sStart="null" offset="1365" sid="r11.benefit.n.0015" wn="2" wnkey="benefit%1:07:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="11303" end="11311" sStart="null" offset="135" sid="r11.benefit.n.0014" wn="2" wnkey="benefit%1:07:00::" text="Although MIRACL and the two aforementioned cohort studies suggest that lipid-lowering agents exert short-term clinical benefits when initiated soon after an acute coronary syndrome, this remains an open question." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="8588" end="8596" sStart="null" offset="305" sid="r11.benefit.n.0013" wn="2" wnkey="benefit%1:07:00::" text="The investigators reasoned that recurrent ischemic events in this population were likely to result from restenosis or bypass graft closure and that statins would be less likely to affect these processes [ 8 ] . Nevertheless, a number of trials have established the benefits of statin therapy early after coronary revascularization [ 9 10 11 ] . Furthermore, a number of recent trials have suggested that higher risk patients with non-ST elevation acute coronary syndromes fair better when an early invasive strategy is applied [ 12 13 14 ] and it is not uncommon for patients to be treated in this fashion." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="7231" end="7238" sStart="null" offset="39" sid="r11.benefit.n.0012" wn="2" wnkey="benefit%1:07:00::" text="While it is impressive that a clinical benefit was realized after only 16 weeks of statin therapy, the increased risk of adverse clinical events persists throughout the year following an acute coronary syndrome." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4917" end="4924" sStart="null" offset="182" sid="r11.benefit.n.0011" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4835" end="4842" sStart="null" offset="100" sid="r11.benefit.n.0010" wn="2" wnkey="benefit%1:07:00::" text="It was also the first trial to identify a short-term (ie, within 16 weeks) clinical benefit from statin therapy; in previous secondary prevention trials, the benefit of statin therapy was not evident for one to two years." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="4709" end="4717" sStart="null" offset="301" sid="r11.benefit.n.0009" wn="2" wnkey="benefit%1:07:00::" text="Although lipid-lowering therapy was associated with a significantly lower mortality when initiated early after an acute coronary syndrome in two large observational studies [ 6 7 ] , MIRACL was the first randomized trial to suggest that statins confer clinical benefits in this setting." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="1048" end="1055" sStart="null" offset="65" sid="r11.benefit.n.0008" wn="2" wnkey="benefit%1:07:00::" text="Whether lipid-lowering therapy would provide incremental benefit if initiated immediately following an acute coronary syndrome is an important issue as the risk of a recurrent adverse cardiac events is much greater in patients with unstable coronary disease than in the stable setting." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10071" end="10078" sStart="null" offset="13" sid="r9.appear.v.0073" wn="1" wnkey="appear%2:39:00::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12091" end="12098" sStart="null" offset="686" sid="r9.appear.v.0045" wn="1" wnkey="appear%2:39:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10071" end="10078" sStart="null" offset="13" sid="r9.appear.v.0073" wn="4" wnkey="appear%2:39:01::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12091" end="12098" sStart="null" offset="686" sid="r9.appear.v.0045" wn="4" wnkey="appear%2:39:01::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10071" end="10078" sStart="null" offset="13" sid="r9.appear.v.0073" wn="1" wnkey="appear%2:39:00::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12091" end="12098" sStart="null" offset="686" sid="r9.appear.v.0045" wn="1" wnkey="appear%2:39:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="10071" end="10078" sStart="null" offset="13" sid="r9.appear.v.0073" wn="1" wnkey="appear%2:39:00::" text="Such therapy appears to be cost effective [ 15 16 ] , especially among high risk patients and is recommended under current American College of Cardiology/American Heart Association guidelines [ 17 ] . Fourth, it may not be possible to ascertain whether these findings apply to all patients with recent acute coronary syndromes regardless of baseline lipid levels." />
    <s path="[MASC]/data/written/1468-6708-3-3.anc" start="12091" end="12098" sStart="null" offset="686" sid="r9.appear.v.0045" wn="1" wnkey="appear%2:39:00::" text="Even if these findings are not confirmed after further study, one could still make a compelling argument that lipid-lowering therapy (barring contraindications) should be initiated early and universally in patients who present with an acute coronary syndrome: First, the long-term safety and effectiveness of statins for the secondary prevention of stable coronary disease is well-established [ 1 2 3 ] ; Second, as evidenced by MIRACL, these agents are safe when initiated at the time of hospitalization for an acute coronary syndrome; Third, the in-hospital initiation of lipid-lowering therapy appears to promote greater long-term utilization of these agents [ 18 19 20 21 ] . Finally, although lipid levels may be unreliable in the setting of an acute coronary syndrome (excepting total :HDL and LDL:HDL cholesterol ratios [ 22 ] ) the overwhelming majority of patients with coronary disease will ultimately require both pharmacologic and non-pharmacologic lipid-lowering interventions to attain recommended cholesterol targets [ 23 24 25 ] ; newer guidelines are even more stringent [ 26 ] . Furthermore, data from the recently presented Heart Protection Study suggest that clinical benefits may accrue independent of baseline cholesterol level [ 4 ] . Thus, to withhold lipid-lowering therapy from patients who present with an acute coronary syndrome would be to accept the status quo, and to date our efforts at cholesterol lowering in the secondary prevention setting have been dismal [ 27 28 ] ." />
  </sentences>
</list>